Skip to main content
SpringerLink
Log in

Prostate Cancer in Special Populations

  • Chapter
  • First Online:
Male Reproductive Cancers

Part of the book series: Cancer Genetics ((CANGENETICS))

  • 807 Accesses

Abstract

Risk factors for prostate cancer have been discussed in detail in a previous chapter by Graham Giles (Chapter 1). As noted by Giles, in addition to the important effect of family history, it is notable that the incidence of prostate cancer varies substantially by ethnicity and nationality. This chapter explores these two factors in more detail, and focuses on special populations in which prostate cancer genetics has been explored in some detail including Icelanders, Poles, Ashkenazi Jews and African-Americans.

Icelanders are an example of a geographical isolate. The population of Iceland is approximately 300,000 individuals, and immigration is uncommon. In addition, there have been several important sudden declines in population, the most notable of which was the arrival of smallpox in 1707 which killed more than one quarter of Iceland’s inhabitants. As a consequence of Iceland’s isolation, genetic heterogeneity may be less pronounced in Iceland compared to other European countries. As discussed by Julius Gudmundsson and Kári Stefánsson, several important low to moderate penetrance prostate cancer alleles were first discovered in this population, and these findings have been subsequently confirmed in many other populations. Founder effects in several disease genes have been demonstrated in Iceland. Perhaps the most well-known cancer-associated mutation is the 999del5 mutation in BRCA2, which is associated with a substantially increased risk for breast cancer and accounts for the vast majority of hereditary breast cancer cases in Iceland. Importantly, as discussed in the chapter by Eeles and colleagues (Chapter 8), this mutation has been shown to be associated with aggressive prostate cancer. The presence of a founder mutation enabled these studies to be conducted, as systematically identifying all BRCA2-postive prostate cancer cases at low cost in an outbred population is not technically feasible at the current time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson, K (2004) Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family. PLoS Med 1(3):e65 Epub 2004 Dec 28

    PubMed  Google Scholar 

  • Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38(6):652–658

    PubMed  CAS  Google Scholar 

  • Baffoe-Bonnie AB, Kiemeney LA, Beaty TH, Bailey-Wilson JE, Schnell AH, Sigvaldason H, Olafsdottir G, Tryggvadottir L, Tulinius H (2002) Segregation analysis of 389 Icelandic pedigrees with Breast and prostate cancer. Genet Epidemiol 23(4):349–363

    PubMed  Google Scholar 

  • Bellanne-Chantelot C, Clauin S, Chauveau D, Collin P, Daumont M, Douillard C, Dubois-Laforgue D, Dusselier L, Gautier JF, Jadoul M, Laloi-Michelin M, Jacquesson L, Larger E, Louis J, Nicolino M, Subra JF, Wilhem JM, Young J, Velho G, Timsit J (2005) Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes 54(11):3126–3132

    PubMed  CAS  Google Scholar 

  • Bergthorsson JT, Johannesdottir G, Arason A, Benediktsdottir KR, Agnarsson BA, Bailey-Wilson JE, Gillanders E, Smith J, Trent J, Barkardottir RB (2000) Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum Genet 107(4):372–375

    PubMed  CAS  Google Scholar 

  • Dong JT. (2006) Prevalent mutations in prostate cancer. J Cell Biochem 97(3):433–447

    PubMed  CAS  Google Scholar 

  • Edghill EL, Bingham C, Ellard S, Hattersley AT (2006) Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet 43(1):84–90

    PubMed  CAS  Google Scholar 

  • Eldon BJ, Jonsson E, Tomasson J, Tryggvadottir L, Tulinius H (2003) Familial risk of prostate cancer in Iceland. BJU Int 92(9):915–919

    PubMed  CAS  Google Scholar 

  • Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103(38):14068–14073

    PubMed  CAS  Google Scholar 

  • Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V, Barkardottir RB (1996) Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 58(4):749–756

    PubMed  CAS  Google Scholar 

  • Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2007a) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39(5):631–647

    PubMed  CAS  Google Scholar 

  • Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2007b) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. doi:10.1038/ng2062

    Google Scholar 

  • Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D (2007) Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39(5):638–644

    PubMed  CAS  Google Scholar 

  • Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB. (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56(16):3663–3665

    PubMed  CAS  Google Scholar 

  • Kasper JS, Giovannucci E. (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062

    PubMed  Google Scholar 

  • Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA. (2003) Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 57(4):326–334

    PubMed  CAS  Google Scholar 

  • Lange EM, Robbins CM, Gillanders EM, Zheng SL, Xu J, Wang Y, White KA, Chang BL, Ho LA, Trent JM, Carpten JD, Isaacs WB, Cooney KA. (2007) Fine-mapping the putative chromosome 17q21–22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. Hum Genet 121(1):49–55

    PubMed  CAS  Google Scholar 

  • Schaid DJ. (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13(1):R103– R121

    PubMed  CAS  Google Scholar 

  • Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ. (2007) A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 67(7):2951–2956

    PubMed  CAS  Google Scholar 

  • Severi G, Hayes VM, Padilla EJ, English DR, Southey MC, Sutherland RL, Hopper JL, Giles GG. (2007) The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 16(3):610–612

    PubMed  CAS  Google Scholar 

  • Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, Jonsson E (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75(10):758–761

    PubMed  CAS  Google Scholar 

  • Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 10(2):225–259

    PubMed  CAS  Google Scholar 

  • Suuriniemi M, Agalliu I, Schaid DJ, Johanneson B, McDonnell SK, Iwasaki L, Stanford JL, Ostrander EA (2007) Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 16(4):809–814

    PubMed  CAS  Google Scholar 

  • Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13(1):117–119

    PubMed  CAS  Google Scholar 

  • Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H. 2007. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99(12):929–935

    PubMed  CAS  Google Scholar 

  • Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 305(6858):855–857

    PubMed  CAS  Google Scholar 

  • Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE. (2002) The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39(7):457–462

    PubMed  CAS  Google Scholar 

  • Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2007) Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 67(7):2944–2950

    PubMed  CAS  Google Scholar 

  • Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TL, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77(2):219–229

    PubMed  CAS  Google Scholar 

  • Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. 2007. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39(5):645–649

    PubMed  CAS  Google Scholar 

  • Antoni L, Sodha N, Collins I, Garrett MD (2007) CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? Nat Rev Cancer 7(12):925–936

    PubMed  CAS  Google Scholar 

  • Cybulski C, Górski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc´ B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, Narod SA, Lubin´ski J (2004a) NBS1 is a prostate cancer susceptibility gene. Cancer Res 64(4):1215–1219

    PubMed  CAS  Google Scholar 

  • Cybulski C, Górski B, Huzarski T, Masojc´ B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szyman´ska A, Szyman´ska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubin´ski J (2004b) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75(6):1131–1135

    PubMed  CAS  Google Scholar 

  • Cybulski C, Huzarski T, Górski B, Masojc´ B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Złowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubin´ski J (2004c) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64(8):2677–2679

    PubMed  CAS  Google Scholar 

  • Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojc´ B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubin´ski J (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43(11):863–866

    PubMed  CAS  Google Scholar 

  • Cybulski C, Wokołorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, Huzarski T, Debniak T, Narod SA, Lubin´ski J (2007) DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 79(1):44–49

    PubMed  CAS  Google Scholar 

  • Cybulski C, Górski B, Gronwald J, Huzarski T, Byrski T, De˛bniak T, Jakubowska A, Wokołorczyk D, Gliniewicz B, Sikorski A, Stawicka S, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Romuald Z, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Posmyk M, Narod SA, Lubin´ski J 2008 BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 17(1):62–66

    PubMed  CAS  Google Scholar 

  • Gayther SA, de Foy KA, Harrington P et al (2000) The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res 60:4513–4518

    PubMed  CAS  Google Scholar 

  • Ikonen, T, Matikainen, MP, Syrjakoski, K, Mononen, N, Koivisto, PA, Rokman, A, Seppala, EH, Kallioniemi, OP, Tammela, TL, Schleutker, J (2003) BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet 40:e98

    PubMed  CAS  Google Scholar 

  • Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59

    PubMed  CAS  Google Scholar 

  • Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS (2006) Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 108(2):638–644

    PubMed  CAS  Google Scholar 

  • Sinclair, CS, Berry, R, Schaid, D, Thibodeau, SN, Couch, FJ (2000) BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60:1371–1375

    PubMed  CAS  Google Scholar 

  • Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, Gozdz S, Sokolenko AP, Krylova NY, Lobeiko OS, Narod SA, Lubinski J (2006) CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 102(3):429–431

    PubMed  CAS  Google Scholar 

  • Thompson D, Easton DF and The Breast Cancer Linkage Consortium (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

    PubMed  CAS  Google Scholar 

  • Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanova E, Cooper PR, Nowak NJ et al (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93:467–476

    PubMed  CAS  Google Scholar 

  • Wu X, Dong X, Liu W, Chen J (2006) Characterization of CHEK2 mutations in prostate cancer. Hum Mutat. 27(8):742–747

    PubMed  CAS  Google Scholar 

  • Złowocka E, Cybulski C, Górski B, Debniak T, Słojewski M, Wokołorczyk D, Serrano-Fernández P, Matyjasik J, van de Wetering T, Sikorski A, Scott RJ, Lubin´ski J (2008) Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int J Cancer 122(3):583–586

    PubMed  Google Scholar 

  • Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 Mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72, 1117–1130

    PubMed  CAS  Google Scholar 

  • Bar-Shira A, Matarasso N, Rosner S, Bercovich D, Matzkin H, Orr-Urtreger A (2006) Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. Prostate 66, 1052–1060

    PubMed  CAS  Google Scholar 

  • Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30, 181–184

    PubMed  CAS  Google Scholar 

  • Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32, 581–583

    PubMed  CAS  Google Scholar 

  • Chen H, Griffin AR, Wu YQ, Tomsho LP, Zuhlke KA, Lange EM, Gruber SB, Cooney KA (2003) RNASEL mutations in hereditary prostate cancer. J Med Genet 40, e21

    PubMed  CAS  Google Scholar 

  • Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Ben BG, Friedman E, Gershoni-Baruch R (2006) The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Fam Cancer 5, 389–395

    PubMed  CAS  Google Scholar 

  • Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72, 1–12

    PubMed  CAS  Google Scholar 

  • Feik E, Baierl A, Madersbacher S, Schatzl G, Maj-Hes A, Berges R, Micksche M, Gsur A (2008) Common genetic polymorphisms of AURKA and prostate cancer risk. Cancer Causes Control 20, 147–152

    Google Scholar 

  • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692–695

    PubMed  CAS  Google Scholar 

  • Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL, Deutsch K, Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP, Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J (2004) Identification of a prostate cancer susceptibility locus on chromosome 7q11–21 in Jewish families. Proc Natl Acad Sci USA 101, 1939–1944

    PubMed  CAS  Google Scholar 

  • Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J (2003) A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40, 787–792

    PubMed  CAS  Google Scholar 

  • Gruber SB, Ellis NA, Rennert G, Offit K, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297, 2013

    PubMed  CAS  Google Scholar 

  • Hamel N, Kotar K, Foulkes WD (2003) Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 4, 7

    PubMed  Google Scholar 

  • Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnaley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Moller P, Maehle L, Badzioch M, Eeles RA, Easton DF, English DR, Southey MC, Hopper JL, Foulkes WD, Giles GG (2005) Macrophage scavenger receptor 1 999C > T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 14, 397–402

    PubMed  CAS  Google Scholar 

  • Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, Sagi M, Abeliovich D (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65, 921–924

    PubMed  CAS  Google Scholar 

  • International CHEK2 collaborative group (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74, 1175–1182

    Google Scholar 

  • Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K (2002) Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39, 611–614

    PubMed  CAS  Google Scholar 

  • Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10, 2918–2921

    PubMed  CAS  Google Scholar 

  • Kotar K, Hamel N, Thiffault I, Foulkes WD (2003) The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 40, e22

    PubMed  CAS  Google Scholar 

  • Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dork T, Neal D, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schurmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O’Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA, Eeles RA (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 17, 2052–2061

    PubMed  CAS  Google Scholar 

  • Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA (2003) Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 57, 326–334

    PubMed  CAS  Google Scholar 

  • Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A (2007) Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia 9, 707–715

    PubMed  CAS  Google Scholar 

  • Miller DC, Zheng SL, Dunn RL, Sarma AV, Montie JE, Lange EM, Meyers DA, Xu J, Cooney KA (2003) Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res 63, 3486–3489

    PubMed  CAS  Google Scholar 

  • Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66, 1259–1272

    PubMed  CAS  Google Scholar 

  • Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, Gammon MD, Ittmann M, Krolewski JJ (1999) Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40, 172–177

    PubMed  CAS  Google Scholar 

  • Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H (2006) RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 15, 474–479

    PubMed  CAS  Google Scholar 

  • Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ (2007) The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 67, 8–13

    PubMed  CAS  Google Scholar 

  • Ostrer H (2001) A genetic profile of contemporary Jewish populations. Nat Rev Genet 2, 891–898

    PubMed  CAS  Google Scholar 

  • Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, Hanna D, Narod SA (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20, 352–357

    PubMed  CAS  Google Scholar 

  • Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr-Urtreger A (2002) A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 71, 981–984

    PubMed  Google Scholar 

  • Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S (1995) Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 9, 152–159

    PubMed  CAS  Google Scholar 

  • Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14, 185–187

    PubMed  CAS  Google Scholar 

  • Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70, 1299–1304

    PubMed  CAS  Google Scholar 

  • Schaid DJ (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13 Spec No 1, R103–R121

    PubMed  CAS  Google Scholar 

  • Seppala EH, Ikonen T, Autio V, Rokman A, Mononen N, Matikainen MP, Tammela TL, Schleutker J (2003) Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 9, 5252–5256

    PubMed  Google Scholar 

  • Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, King MC (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14, 555–563

    PubMed  CAS  Google Scholar 

  • Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274, 1371–1374

    PubMed  CAS  Google Scholar 

  • Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11, 198–200

    PubMed  CAS  Google Scholar 

  • Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336, 1401–1408

    PubMed  CAS  Google Scholar 

  • Sun J, Hsu FC, Turner AR, Zheng SL, Chang BL, Liu W, Isaacs WB, Xu J (2006) Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 66, 728–737

    PubMed  CAS  Google Scholar 

  • Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94, 1358–1365

    PubMed  CAS  Google Scholar 

  • Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD (2008) Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 270,173–180.

    Google Scholar 

  • Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E (2000) The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83, 463–466

    PubMed  CAS  Google Scholar 

  • Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2002) Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 71, 116–123

    PubMed  CAS  Google Scholar 

  • Wang L, McDonnell SK, Cunningham JM, Hebbring S, Jacobsen SJ, Cerhan JR, Slager SL, Blute ML, Schaid DJ, Thibodeau SN (2003) No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet 35, 128–129

    PubMed  CAS  Google Scholar 

  • Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon C, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91, 1241–1247

    PubMed  CAS  Google Scholar 

  • Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H, Isaacs SD, Wiley K, Bujnovsky P, Meyers DA, Walsh PC, Isaacs WB (1999) No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 39, 280–284

    PubMed  CAS  Google Scholar 

  • Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA (2002) Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32, 321–325

    PubMed  CAS  Google Scholar 

  • Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TL, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77, 219–229

    PubMed  CAS  Google Scholar 

  • Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, Gruber SB, Ostrander EA, Cooney KA (2004) Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clin Cancer Res 10, 5975–5980

    PubMed  CAS  Google Scholar 

  • Ahaghotu C, Baffoe-Bonnie A et al (2004) Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis 7(2):165–169

    PubMed  CAS  Google Scholar 

  • Amundadottir LT, Sulem P et al (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38(6):652–658

    PubMed  CAS  Google Scholar 

  • Baffoe-Bonnie AB, Kittles RA et al (2007) Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer Study (AAHPC). Prostate 67(1):22–31.

    PubMed  CAS  Google Scholar 

  • Bangsi D, Zhou J et al (2006) Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 24(1):21–27.

    PubMed  CAS  Google Scholar 

  • Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, Land SJ,Wenzlaff AS, Reich D, McKeigue P, Chen W, Heath EI, Powell IJ, Kittles RA, Rybicki BA. Hum Genet. 2009 Jul 1. [Epub ahead of print]

    Google Scholar 

  • Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, Sun J, Isaacs SD, Wiley KE, Kim ST, Hsu FC, Wu W, Torti FM, Walsh PC, Chang BL, Isaacs WB. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2145-9.

    Google Scholar 

  • Camp NJ, Farnham JM et al (2006). Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. Cancer Res 66(20):10205–10212

    PubMed  CAS  Google Scholar 

  • Camp NJ, Cannon-Albright LA et al; International Consortium for Prostate Cancer Genetics (2007) Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet 1;16 (11):1271–1278

    Google Scholar 

  • Carter BS, Beaty TH et al (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89(8):3367–3371

    PubMed  CAS  Google Scholar 

  • Carter BS, Bova GS et al (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150(3):797–802

    PubMed  CAS  Google Scholar 

  • Clegg L, Li FP, Hankey BF, Chu K, Edwards BK (2002). Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 162(17):1985–1993

    PubMed  Google Scholar 

  • Crawford ED (2003) Epidemiology of prostate cancer. Urology 62(6 Suppl 1):3–12

    PubMed  Google Scholar 

  • Cunningham GR, Ashton CM et al (2003) Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate 56(4):256–262

    PubMed  Google Scholar 

  • deVere White R, Deitch A et al (1998) Racial differences in clinically localized prostate cancers of black and white men. J Urol 159(6):1979–1982

    PubMed  CAS  Google Scholar 

  • Freedman ML, Haiman CA et al (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103(38):14068–14073

    PubMed  CAS  Google Scholar 

  • Goode EL, Stanford JL et al (2001) Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res 7(9):2739–2749

    PubMed  CAS  Google Scholar 

  • Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859–864

    PubMed  Google Scholar 

  • Grossfeld GD, Latini DM et al (2002). Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 168(6):2510–2515

    PubMed  Google Scholar 

  • Gudmundsson J, Sulem P et al (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631–637

    PubMed  CAS  Google Scholar 

  • Haiman CA, Patterson N et al (2007) Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39(5):638–644

    PubMed  CAS  Google Scholar 

  • Iselin CE, Box JW et al (1998) Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 83(11):2353–2360

    PubMed  CAS  Google Scholar 

  • Kittles RA, Baffoe-Bonnie AB et al. (2006) A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43(6): 507–511

    PubMed  CAS  Google Scholar 

  • McKeigue PM (1997) Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am J Hum Genet 60:188–196

    PubMed  CAS  Google Scholar 

  • Moul, JW, Douglas TH et al (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155(5):1667–1673

    PubMed  CAS  Google Scholar 

  • Narain V, Cher ML et al (2002) Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev 21(1):17–27

    PubMed  Google Scholar 

  • Ntais C, Polycarpou A et al (2003) Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12(2):120–126

    PubMed  CAS  Google Scholar 

  • Ostrander EA and Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67(6):1367–1375

    PubMed  CAS  Google Scholar 

  • Powell IJ (2007) Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 177(2):444–449

    PubMed  Google Scholar 

  • Powell IJ Meyskens FL Jr. (2001) African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urology 57(4 Suppl 1):178–181

    PubMed  CAS  Google Scholar 

  • Powell IJ, Carpten J et al (2001) African-American heredity prostate cancer study: a model for genetic research. J Natl Med Assoc 93(12 Suppl): 25S–28S

    PubMed  CAS  Google Scholar 

  • Powell IJ, Dey J et al (2002) Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology 59(6):907–912

    PubMed  Google Scholar 

  • Powell IJ, Zhou J. et al (2004) CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 172(5 Pt 1):1848–1852

    PubMed  Google Scholar 

  • Rebbeck TR, Jaffe JM et al (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90(16):1225–1229

    PubMed  CAS  Google Scholar 

  • Royal C, Baffoe-Bonnie A et al. (2000) Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol 10(8 Suppl):S68–S77

    PubMed  CAS  Google Scholar 

  • Schaid, D. (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13:R103–R121 [Epub ahead of print].

    Google Scholar 

  • Schumacher FR, Feigelson HS et al (2007) A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 67(7):2951–2956

    PubMed  CAS  Google Scholar 

  • Smith, JR, Freije D et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274(5291):1371–1374

    PubMed  CAS  Google Scholar 

  • Smith MW, Patterson N et al (2004) A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet 74(5):1001–1013

    PubMed  CAS  Google Scholar 

  • Suuriniemi M, Agalliu I et al (2007) Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 16(4):809–814

    PubMed  CAS  Google Scholar 

  • Wang L, McDonnell SK et al (2007) Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 67(7):2944–2950

    PubMed  CAS  Google Scholar 

  • Zeigler-Johnson, C. (2001) CYP3A4: a potential prostate cancer risk factor for high-risk groups. Clin J Oncol Nurs 5(4):153–154

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, 546 Pine Avenue West, Montreal, QC, Canada, H2W 1S6

    William D. Foulkes

  2. deCODE genetics, Sturlugata 8, 101, Reykjavik, Iceland

    Julius Gudmundsson & Kári Stefánsson

  3. Department of Genetics and Pathomorphology, Pomeranian Medical University, PL –70-111 Szczecin, al. Powstanco Wlkp. 72, Pomerania, Poland

    Cezary Cybulski & Jan Lubiński

  4. Cancer Genetics Program, Departments of Oncology and Human Genetics, McGill University, 546 Pine Avenue West, Montreal, QC, Canada, H2W 1S6

    William D. Foulkes & Sabrina Notte

  5. Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Agnes B. Baffoe-Bonnie & Isaac J. Powell

  6. Inherited Disease Research Branch National Human Genome Research Institute, National Institutes of Health, 333 Cassell Drive, Suite 1200, Baltimore, MD, 21224, USA

    Agnes B. Baffoe-Bonnie & Isaac J. Powell

  7. Department of Epidemiology, Now at Merck Research Laboratories, North Wales, PA, 19454, USA

    Agnes B. Baffoe-Bonnie & Isaac J. Powell

Authors
  1. William D. Foulkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julius Gudmundsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kári Stefánsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cezary Cybulski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan Lubiński
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William D. Foulkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabrina Notte
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Agnes B. Baffoe-Bonnie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Isaac J. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kári Stefánsson , Jan Lubiński , William D. Foulkes or Agnes B. Baffoe-Bonnie .

Editor information

Editors and Affiliations

  1. Dept. Oncology & Human Genetics, McGill University , Montreal, H2W 1S6, Canada

    William D. Foulkes

  2. Health System, University of Michigan, Ann Arbor, 48109, U.S.A.

    Kathleen A. Cooney

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Foulkes, W.D. et al. (2010). Prostate Cancer in Special Populations. In: Foulkes, W., Cooney, K. (eds) Male Reproductive Cancers. Cancer Genetics. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0449-2_9

Download citation

Publish with us

Policies and ethics

Search

Navigation